HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kohei Kaku Selected Research

mitiglinide

6/2014Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy.
11/2013Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
7/2013Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
1/2009Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kohei Kaku Research Topics

Disease

129Type 2 Diabetes Mellitus (MODY)
10/2022 - 08/2002
24Hypoglycemia (Reactive Hypoglycemia)
10/2022 - 10/2007
22Diabetes Mellitus
10/2022 - 08/2002
20Insulin Resistance
10/2022 - 03/2005
18Body Weight (Weight, Body)
03/2021 - 06/2004
14Type 1 Diabetes Mellitus (Autoimmune Diabetes)
11/2022 - 01/2009
14Hyperglycemia
10/2022 - 07/2013
11Atherosclerosis
12/2020 - 04/2010
8Weight Loss (Weight Reduction)
09/2021 - 01/2019
8Diabetic Nephropathies (Diabetic Nephropathy)
09/2019 - 08/2002
7Infections
10/2022 - 10/2018
6Neoplasms (Cancer)
01/2022 - 01/2016
6Weight Gain
09/2021 - 01/2009
6Glucose Intolerance
03/2015 - 08/2008
5Drug-Related Side Effects and Adverse Reactions
04/2022 - 09/2016
5Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 04/2010
5Hypertension (High Blood Pressure)
01/2021 - 11/2011
5Edema (Dropsy)
06/2017 - 01/2009
4Diabetic Ketoacidosis (Ketoacidosis, Diabetic)
10/2022 - 02/2020
4Urinary Tract Infections (Urinary Tract Infection)
10/2022 - 10/2017
4Hypertriglyceridemia
06/2021 - 11/2007
4Constipation
01/2021 - 01/2018
4Obesity
01/2020 - 04/2016
4Carotid Artery Diseases
02/2019 - 11/2010
3Hypersensitivity (Allergy)
10/2022 - 01/2009
3Heart Failure
01/2022 - 01/2017
3Arteriosclerosis
07/2021 - 11/2017
3Non-alcoholic Fatty Liver Disease
06/2021 - 01/2019
3Fatty Liver
03/2021 - 07/2016
3Pain (Aches)
01/2021 - 01/2016
3Graves Disease (Basedow Disease)
08/2020 - 12/2016
3Pancreatitis
11/2019 - 11/2007
3Hypercholesterolemia
11/2018 - 04/2010
2Diabetes Complications
10/2022 - 01/2022
2Osteomalacia
01/2022 - 01/2016
2Hypophosphatemia
01/2022 - 01/2016
2Autoimmune Pancreatitis
01/2022 - 12/2019
2Bullous Pemphigoid (Pemphigoid)
01/2022 - 11/2019
2Autoimmune Diseases (Autoimmune Disease)
01/2022 - 08/2018
2Stroke (Strokes)
01/2022 - 01/2017

Drug/Important Bio-Agent (IBA)

52Glucose (Dextrose)FDA LinkGeneric
10/2022 - 06/2004
47Insulin (Novolin)FDA Link
10/2022 - 08/2008
25Hypoglycemic Agents (Hypoglycemics)IBA
01/2022 - 01/2009
206- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
02/2021 - 03/2014
17SodiumIBA
10/2022 - 07/2013
17Sodium-Glucose Transporter 2 InhibitorsIBA
03/2021 - 11/2013
12Sodium-Glucose Transport ProteinsIBA
01/2020 - 04/2014
10Pharmaceutical PreparationsIBA
04/2022 - 10/2007
10Blood Glucose (Blood Sugar)IBA
01/2022 - 09/2009
10Dipeptidyl-Peptidase IV InhibitorsIBA
01/2021 - 02/2014
10Pioglitazone (Actos)FDA Link
11/2020 - 03/2005
10LipidsIBA
01/2020 - 08/2002
9Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
02/2021 - 06/2012
8IncretinsIBA
03/2022 - 07/2013
8insulin degludecIBA
03/2022 - 01/2013
8trelagliptinIBA
03/2020 - 02/2014
8LiraglutideFDA Link
12/2019 - 08/2011
7empagliflozinIBA
10/2022 - 01/2017
7ipragliflozinIBA
12/2021 - 07/2018
7Sitagliptin Phosphate (Januvia)FDA Link
01/2021 - 11/2013
7alogliptinIBA
11/2019 - 09/2011
6Glucagon-Like Peptide-1 ReceptorIBA
07/2021 - 11/2017
5AntibodiesIBA
01/2022 - 04/2019
5SymportersIBA
01/2022 - 12/2014
5Glucagon-Like Peptide 1 (GLP 1)IBA
07/2021 - 08/2011
5Metformin (Glucophage)FDA LinkGeneric
03/2021 - 05/2009
5voglibose (Basen)IBA
06/2014 - 05/2009
4Transcription Factors (Transcription Factor)IBA
03/2022 - 01/2005
4SteroidsIBA
01/2022 - 01/2015
4AdiponectinIBA
11/2020 - 05/2009
4glimepiride (Amarel)FDA LinkGeneric
11/2020 - 12/2012
4CanagliflozinIBA
01/2020 - 12/2015
4Insulin Glargine (Lantus)FDA Link
01/2018 - 01/2013
41,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA
04/2016 - 01/2015
4mitiglinideIBA
06/2014 - 01/2009
4Rosuvastatin Calcium (Crestor)FDA Link
01/2014 - 04/2010
3Thyrotropin (Thyroid-Stimulating Hormone)FDA Link
01/2022 - 01/2021
3Anti-Bacterial Agents (Antibiotics)IBA
07/2021 - 01/2019
3Lipoproteins (Lipoprotein)IBA
06/2021 - 08/2002
3Triglycerides (Triacylglycerol)IBA
06/2021 - 01/2016
3Nonesterified Fatty Acids (NEFA)IBA
01/2020 - 05/2009
3CholesterolIBA
08/2019 - 05/2009
3Hydrocortisone (Cortisol)FDA LinkGeneric
04/2019 - 01/2015
3mizagliflozinIBA
04/2019 - 01/2018
3Adrenocorticotropic Hormone (ACTH)FDA Link
04/2019 - 01/2015
3C-Reactive ProteinIBA
01/2019 - 03/2016
3AlbuminsIBA
01/2018 - 01/2015
3repaglinide (Prandin)FDA Link
03/2016 - 06/2012
3ThiazolidinedionesIBA
07/2015 - 02/2010
3Pravastatin (Pravachol)FDA LinkGeneric
01/2013 - 04/2010
2Hemoglobins (Hemoglobin)IBA
11/2022 - 11/2016
2KetonesIBA
10/2022 - 08/2019
2Thyroid HormonesIBA
01/2022 - 01/2022
2Thyroxine (Levothyroxine)FDA LinkGeneric
01/2022 - 01/2021

Therapy/Procedure

65Therapeutics
01/2022 - 01/2009
36Glycemic Control
01/2022 - 01/2009
5Exercise Therapy (Therapy, Exercise)
03/2020 - 11/2011
3Renal Dialysis (Hemodialysis)
03/2020 - 01/2016
3Secondary Prevention
11/2018 - 04/2010
2Surgical Amputation (Amputations)
10/2022 - 02/2020